Oramed Pharmaceuticals Inc.

oramed.com

Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.

Related News

BUSINESS INSIGHTS

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

news image

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

POLL: UTAH VOTERS BACK CAP ON CO-PAYS FOR INSULIN PRESCRIPTIONS

Public News Service | January 14, 2020

news image

The skyrocketing cost of prescription drugs has become a bipartisan issue among voters, and Utahns overwhelmingly back a plan to help diabetics overcome the cost of life-saving insulin. A new poll from UtahPolicy.com Y-2 Analytics finds 4 out of 5 registered voters would support legislation to cap out-of-pocket costs for insulin. The idea mirrors a bill passed in Colorado in 2019 to limit a patient's out-of-pocket costs for insulin, a hormone critical to diabetics for controlling their blood...

Read More

ROCHE AND ILLUMINA FORGE GENOMICS ALLIANCE FOR CANCER TESTING

pharma news | January 14, 2020

news image

Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS player – Pacific Biosciences or PacBio – after concluding it would be unlikely to make it past antitrust regulators in the US and UK. Illumina is thought to have around 80% of the DNA sequ...

Read More
news image

BUSINESS INSIGHTS

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

POLL: UTAH VOTERS BACK CAP ON CO-PAYS FOR INSULIN PRESCRIPTIONS

Public News Service | January 14, 2020

The skyrocketing cost of prescription drugs has become a bipartisan issue among voters, and Utahns overwhelmingly back a plan to help diabetics overcome the cost of life-saving insulin. A new poll from UtahPolicy.com Y-2 Analytics finds 4 out of 5 registered voters would support legislation to cap out-of-pocket costs for insulin. The idea mirrors a bill passed in Colorado in 2019 to limit a patient's out-of-pocket costs for insulin, a hormone critical to diabetics for controlling their blood...

Read More
news image

ROCHE AND ILLUMINA FORGE GENOMICS ALLIANCE FOR CANCER TESTING

pharma news | January 14, 2020

Roche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, but has compensated for that with a 15-year alliance focusing on cancer genomics. The new deal comes after Illumina called off a $1.2 billion merger agreement with another NGS player – Pacific Biosciences or PacBio – after concluding it would be unlikely to make it past antitrust regulators in the US and UK. Illumina is thought to have around 80% of the DNA sequ...

Read More